Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VXA-CoV2-1.1-S
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Vaxart
Deal Size : Not Applicable
Deal Type : Not Applicable
Syngene Set For Phase-2 Trial Of Covid Oral Tablet Vaccine
Details : VXA-CoV2-1, an oral tablet COVID-19 vaccine triggers mucosal immune responses in humans, is believed to be the first defense against airborne viruses, such as coronavirus and flu.
Brand Name : VXA-CoV2-1.1-S
Molecule Type : Vaccine
Upfront Cash : Not Applicable
October 11, 2022
Lead Product(s) : VXA-CoV2-1.1-S
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Vaxart
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
Syngene International extends Long Term Research Collaboration with Bristol Myers Squibb until 2030
Details : The collaboration has been extended through the end of 2030 and will expand the breadth of drug discovery research conducted, including chemistry, biology, drug metabolism and pharmacokinetics, as well as translational medicine research and pharmaceutica...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
April 26, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
